Table 1. Prior case reports describing ALK inhibitor use after drug-induced pneumonitis.
| Case Report | Demographics | Initial ALK TKI | Time to Onset of DI-ILD1 | Re-treatment ALK TKI |
|---|---|---|---|---|
| Asai et al. (19) | 70 yo F | Crizotinib | 35 days | Crizotinib |
| Asai et al. (20) | 60 yo M | Crizotinib | 50 days | Crizotinib |
| Bender et al. (21) | 53 yo F | Ceritinib | 7 months | Crizotinib Brigatinib |
| Chino et al. (22) | 46 yo F | Crizotinib | 47 days | Alectinib |
| Doménech et al. (23) | 45 yo F | Crizotinib | 9 days | Brigatinib |
| Fujiuchi et al. (24) | 70 yo F | Crizotinib | 60 days | Alectinib |
| Hwang et al. (25) | 46 yo F | Alectinib | 28 days | Alectinib |
| Lim et al. (26) | 45 yo F | Ceritinib | 6 months | Ceritinib |
| Maka et al. (27) | 47 yo F | Crizotinib | 60 days | Crizotinib |
| Nitawaki et al. (28)2 | 57 yo M | Alectinib | 33 days | Alectinib |
| 64 yo F | Alectinib | 12 months | Alectinib | |
| Nukaga et al. (29) | 63 yo M | Crizotinib | 27 days | Alectinib |
| Tachihara et al. (30) | 70 yo M | Crizotinib | 25 days | Crizotinib |
| Yanagisawa et al. (31) | 53 yo F | Crizotinib | 10 days | Crizotinib |
1Time of onset is defined is the duration in days or months from initiation of ALK targeted therapy to presentation with DI-ILD, 2Two cases described in the same case series. ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; DI-ILD, drug-induced interstitial lung disease.